Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009180
Filing Date
2025-05-08
Accepted
2025-05-08 09:30:20
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 867621
2 EX-31.1 ex31-1.htm EX-31.1 15374
3 EX-31.2 ex31-2.htm EX-31.2 17007
4 EX-32.1 ex32-1.htm EX-32.1 4901
5 EX-32.2 ex32-2.htm EX-32.2 5131
6 GRAPHIC form10-q_001.jpg GRAPHIC 118386
  Complete submission text file 0001641172-25-009180.txt   5068088

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE lpcn-20250331.xsd EX-101.SCH 34934
8 XBRL CALCULATION FILE lpcn-20250331_cal.xml EX-101.CAL 41733
9 XBRL DEFINITION FILE lpcn-20250331_def.xml EX-101.DEF 161606
10 XBRL LABEL FILE lpcn-20250331_lab.xml EX-101.LAB 347707
11 XBRL PRESENTATION FILE lpcn-20250331_pre.xml EX-101.PRE 285115
68 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 623207
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36357 | Film No.: 25924216
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)